We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Vivomedica | VVM | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.10 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.10 | 0.10 |
| Top Posts |
|---|
Posted at 18/8/2010 07:48 by pc4900074200 diggerI am STILL owed shares from a deal done with Barclays Stockbrokers, I will be contacting them pointing out that the MM concerned will now not be able to complete the contract undertaken between myself and them, asking for a full refund of the outstanding balance. Some light for me at the end of the tunnel as I should get a small return for some of my VVM investment? Will post result of that in due cource. pc |
Posted at 08/3/2010 15:45 by digger27 fez - not heard owt but just tried to access VVM website and can't connect. HmmmIt's back up and no updates so can only assume no news. |
Posted at 22/2/2010 11:53 by pc4900074200 H, not buying - bought on last day of trading and Barclays took the order and money but could not fill. Hence still waiting for full amount.My point was that even after de-listing the market makers are still finding shares to be able to send me a cert. I have outstanding, 100k's worth for them to fill. There must be trading going on for them to be able find them? Where, is an unknown. Have you emailed VVM asking about what they are doing about it? pc |
Posted at 15/9/2009 12:47 by alwaysbanking Digger27 got my VVM in certificated form and heard absolutely JACK. |
Posted at 04/5/2009 11:07 by alwaysbanking I have 10000 shares in VVM in Certificated format in my possession, (besides the obvious) What should I do with them and am I still a share holder of this now unlisted and potentially defunct investment. |
Posted at 14/4/2009 12:25 by pc4900074200 dig, you never know we may meet in the future at a meeting when we might justturn the tables on VVM if there are a group of PI's left holding more than 20m? pc :-] |
Posted at 20/3/2009 14:08 by pc4900074200 From the total lack of posts from any of the regulars and the absence ofany other PI's posts I take it that VVM is 'dead on the ground'. So far today has seen 2% of the ten that if retained would have allowed PI's some future leverage. I will be retaining my shares and have already sent the proxy form back with a rejection mark in place. Though, it will be of little effect to the pending result. The Management will be pleased with the slow but steady flow of sells as another company slowly slips out of AIM. and another group of investors are fleeced of their money. On de-list day I will tidy the header removing the charts etc. leaving just the details of Company and a link to the website for any remaining shareholders to use. pc |
Posted at 18/3/2009 08:55 by malctim70 My sympathies to the guy who was robbed in 40 min the other day....I take no comfort from any shares being traded on aim.....like many, I am sick of the outrageous spreads (especially this one) the manipulation, the corruption and the downright criminal (I was one of the poor sods in lgb). Leaving aim does'nt bother me at all....It is like taking a step back in time to how the stockmarket used to be run.... My concern is whether VVM has what it takes to survive and prosper and what do the new financial backers want in return for their money.....questions we may have to wait a while for the answers...... |
Posted at 12/3/2009 11:26 by digger27 MalcTim70 - interesting to hear that. I believe the technology that VVM has will work but they ran out of time and rather than go into admin saw this as a way to survive. Merlin have invested heavily so must see value in the IP and so must these mystery financiers. Just dont want them to take it from us. These comments from the AGM have a hollow ring to them now...Commenting on the update, Professor Sir Christopher Evans, Chairman VivoMedica said: " I am delighted that VivoMedica's world leading innovations in drug discovery and other aspects of human medical research have recently been so well received by the pharmaceutical industry and several global and medtech companies. Our safety data for drugs using our unique DrugPrint and human stem cells is unparalleled in this industry and I am very excited at the prospects already developing for our world beating PathScore technology. There is plenty more to come from VivoMedica in 2008". |
Posted at 01/12/2008 06:20 by oneillshaun Sorry to say to guys but that is it I am done with VVM it is going nowhere fast the money raised will be burnt in a short time I am not buying another share in VVM to many other good targets out there that i can make money on, I am not selling I will hold, wish you luck.RNS Number : 9735I Vivomedica PLC 26 November 2008 VivoMedica plc (the 'Company') 26 November 2008 Notice of General Meeting The Company announces that it has today posted a circular to shareholders setting out various resolutions to be passed at the Company's General Meeting to be held on 18 December 2008. These resolutions include a proposed share capital reorganisation, which will enable a Proposed Placing of securities in order to fund the continued development of the business. The circular is available for download at the Company's website: www.vivomedica.com The full text of the Chairman's letter contained within the circular is set out below. Definitions in this announcement shall bear the same meaning as those in the circular to Shareholders. To the holders of Ordinary Shares and, for information only, to holders of options over Ordinary Shares Dear Shareholder, Proposed Share Capital Reorganisation and Notice of General Meeting 1. Introduction VivoMedica has today announced a proposal to reorganise the Company's share capital by way of the Share Capital Reorganisation conditional upon Shareholder approval to be sought at a General Meeting, details of which are set out below. The Directors stated in the Company's interim results for the six months to 30 June 2008 that in order to continue the Group's progress to date further funds would be required. The Directors consider that it would be in the best interests of the Company to seek to raise such new funds through the Proposed Placing. The Companies Act prohibits the Company from issuing Ordinary Shares at a discount to their nominal value and it will, therefore, be necessary to reorganise the share capital of the Company to allow the Proposed Placing to take place. As such, the Proposed Placing is conditional upon the passing of the Resolutions in relation to the Share Capital Reorganisation. Authority for the Share Capital Reorganisation will be sought from Shareholders at a General Meeting convened for 11.00 am on 18 December 2008. Further details of the Share Capital Reorganisation are set out below and details of the General Meeting are set out in the Notice of General Meeting at the end of this document. The purpose of this document is to give the background to and reasons for the Proposed Placing, the Share Capital Reorganisation, to explain why your Board considers that the Proposal is in the best interests of the Company and its Shareholders as a whole and to recommend that you vote in favour of the Resolutions at the forthcoming General Meeting. 2. The Placing At the Annual General Meeting, the Shareholders passed certain resolutions which, amongst other matters, authorised the Company to issue shares on a non-pre-emptive basis in connection with a financing up to an aggregate nominal amount of £4,500,000. The Board believes that it remains in the best interests of the Company to raise further finance by way of the Proposed Placing. Subject to the passing of the Resolutions, the decision as to whether or not to proceed with the Proposed Placing will be determined by the Board at such time as the Board believes it appropriate to do so, having regard to market conditions. New Ordinary Shares issued pursuant to the Proposed Placing will, if issued, rank in full for all dividends and otherwise pari passu with the then existing New Ordinary Shares. The Board will seek the advice of its Nominated Adviser and Broker in connection with the Proposed Placing and as to which potential investors New Ordinary Shares may be offered as part of the Proposed Placing. The net proceeds of the Proposed Placing will be used to continue to fund the development of our two key technologies PathscoreTM and DrugPrint® and for other general working capital purposes. 3. Background to and reasons for the Share Capital Reorganisation At the time of the Company's interim results for the six months to 30 June 2008, the Directors reported on the significant progress the Company had made towards delivering high value solutions to the pharmaceutical industry and in realising the commercial value of the Company's exclusive worldwide technology licences. We also stated that the nature of the Group's operations means that VivoMedica's future income is dependent on securing collaboration agreements and/or sales/sub-licensing contracts within the markets it currently operates in, and on developing new applications for the PathscoreTM and DrugPrint® products. As a result there can be a considerable and unpredictable variation in the timing and amount of cash inflows generated from planned product launches. We therefore announced that in order to continue the Group's progress to date, further funds would be required. The Directors therefore intend to seek to raise new funds via the Proposed Placing. 4. Details of the Share Capital Reorganisation The closing mid-market price of an Existing Ordinary Share was 0.7p on 25 November 2008, being the last dealing date prior to the publication of this document. The Company's share price is therefore below the nominal value of an Ordinary Share of 2 pence each. In effect this prohibits the Company from raising any further equity capital as, in order to comply with the Companies Act, any further shares issued would have to be issued at a price at or above the nominal value. Consequently, the Board proposes to sub-divide the shares as detailed below and reduce the nominal value of each Existing Ordinary Share to 0.1 pence per share. Resolution 1 to be proposed at the General Meeting and as set out at the end of this document, proposes that each Existing Ordinary Share of 2 pence each in nominal value be sub-divided into one New Ordinary Share of 0.1 pence each in nominal value and one new Deferred Share of 1.9 pence each in nominal value. The New Ordinary Shares of 0.1 pence each so created will continue to carry the same rights as attach to the Existing Ordinary Shares of 2 pence each (save for the reduction in nominal value). Following the Share Capital Reorganisation, the Company's authorised share capital will remain at £14,000,000 comprising 700,000,000 New Ordinary Shares and 700,000,000 Deferred Shares and the Company's issued share capital will comprise 200,555,662 New Ordinary Shares and 200,555,662 Deferred Shares. 5. Share Rights The New Ordinary Shares arising on completion of the Share Capital Reorganisation will have the same rights as the Existing Ordinary Shares, including without limitation, the same voting, dividend and other rights. The Deferred Shares will be transferable only with the consent of the Company and will not be admitted to trading on any market or exchange. The Deferred Shares will not confer on their holders any right to receive notice of any general meeting of the Company nor any right to attend, speak or vote at any such meeting. The Deferred Shares will not entitle their holders to receive any dividend or other distribution and shall on a return of assets in a winding up of the Company entitle the holders only to the repayment of the amounts paid up on such shares after the amount paid to holders of the New Ordinary Shares exceeds £700,000,000 per New Ordinary Share. The Deferred Shares will also be incapable of transfer and no share certificates will be issued in respect of them. The Directors consider that the Deferred Shares to be of no economic value. The Deferred Shares will, subject to Shareholder approval pursuant to Resolution 2 to be proposed at the General Meeting, be re-purchased by the Company, pursuant to a contract for purchase approved in accordance with Resolution 1, for 1 pence in aggregate for all such shares and following such repurchase will be cancelled. The repurchase of the Deferred Shares will be financed out of the proceeds of the issue of 1 Existing Ordinary Share by the Company to be subscribed by an existing shareholder at a subscription price equal to the nominal value of such share. 6. General Meeting A notice convening the General Meeting to be held at the offices of Buchanan Communications, 45 Moorfields, London EC2Y 9AE at 11.00 am on 18 December 2008 is set out at the end of this document. At the General Meeting, the following Resolutions will be proposed: (1) a special resolution to: (A) sub-divide each Existing Ordinary Share into one New Ordinary Share with a nominal value of 0.1 pence and one Deferred Share with a nominal value of 1.9 pence; and (B) amend the Articles to reflect the creation of the Deferred Shares; and (2) conditional on passing Resolution 1, an ordinary resolution to authorise the Directors to repurchase the Deferred Shares pursuant to a contract for purchase. 7. Action to be taken A Form of Proxy for use by Shareholders in connection with the General Meeting accompanies this document. Whether or not you intend to be present at the General Meeting, you are requested to complete and sign the Form of Proxy and return it to the Company's Registrars, Capita Registrars, Proxies, The Registry, 34 Beckenham Road, Beckenham, Kent, BR3 4TU, so as to be received no later than 48 hours before the commencement of the General Meeting. Unless the Form of Proxy is received by the date and time mentioned in the instructions, it will be invalid. The completion and return of the Form of Proxy will not prevent you from attending the General Meeting and voting in person, if you so wish. 8. Recommendation The Directors consider the Resolutions to be in the best interests of the Company and therefore, unanimously recommend Shareholders to vote in favour of the Resolutions at the General Meeting as they intend to do in respect of their own beneficial holdings of 4,322,857 Ordinary Shares representing 2.16 per cent. of the issued share capital at the date of this document. Funds managed by Merlin Biosciences Limited have undertaken to vote in favour of the Resolutions in respect of their shareholdings which amount to 100,257,775 Ordinary Shares which represent approximately 49.99 per cent. of the issued share capital at the date of this document. Yours faithfully Sir Christopher Evans Chairman Contact: Buchanan Communications 020 7466 5000 Tim Anderson / Catherine Breen Brewin Dolphin Investment Banking (NOMAD) 0845 270 8600 Mark Brady / Alison Barrow This information is provided by RNS The company news service from the London Stock Exchange |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
